Objectives: This study sought to evaluate the efficacy of plasmapheresis plus low-dose intravenous immunoglobulin in highly sensitized patients waiting for a deceased-donor renal transplant. Materials and Methods: Thirty-five highly sensitized patients (HLA class I panel reactive antibody > 50%) received plasmapheresis, plus low-dose intravenous immunoglobulin treatment. In 25 patients (group 1), a positive T- and/or B-cell cytotoxicity crossmatch was rendered negative by plasmapheresis, plus low-dose intravenous immunoglobulin treatment. Two patients did not receive renal transplants owing to persistent positive crossmatch. Eight patients already had a negative crossmatch before desensitization. During the same time, 32 highly sensitized patients (group 2), without desensitization, had a negative crossmatch and received deceased-donor renal transplants. Results: Group 1 showed a numerically higher rate of acute rejection (32.0% vs 21.9%; P =.6) and antibody-mediated rejection (20.0% vs 9.4%; P =.3), but the difference was not statistically significant. Four of 5 cases of antibody-mediated rejection in group 1 had a peak donor specific antibody titer ≥ 1:8. Comparable mean serum creatinine levels at 24 months were observed (group 1: 130 ± 38 μmol/L vs group 2: 123 ± 41 μmol/L; P =.5). No difference in Kaplan-Meier graft survival was found between group 1 and group 2 after follow-up of 52 ± 26 months (P =.7). Conclusions: Desensitization with plasmapheresis, plus low-dose intravenous immunoglobulin enables successful deceased-donor renal transplant in highly sensitized patients with a positive crossmatch. Antibody-mediated rejection occurred predominantly in recipients with donor-specific antibodies of high titers.
|Original language||English (US)|
|Journal||Experimental and Clinical Transplantation|
|State||Published - Jan 1 2010|
- Antibody-mediated rejection
- Hla antibodies
- Kidney transplantation
ASJC Scopus subject areas